Malaria Radical Cure Drug Efficacy Clinical Study
Closed Pre-Solicitation Posted
Not the latest version. See the latest special notice from .
- Solicitation number
- HT942526R0999
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Place of performance
- Syracuse, New York, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency, through the Walter Reed Army Institute of Research (WRAIR) and Armed Forces Research Institute of Medical Sciences (AFRIMS), is seeking research and development services to conduct clinical studies on malaria radical cure drug efficacy. The primary focus involves evaluating tafenoquine, an anti-malarial drug, through clinical trials that measure its efficacy in treating malaria in Thailand and its safety and pharmacokinetics in U.S. healthy adults. Respondents must demonstrate capability in conducting clinical research, including recruitment and enrollment of study participants, drug administration, safety monitoring, and scientific publication of results. This Request for Information (RFI) is issued solely for market research purposes and does not constitute a formal solicitation; responses must be submitted electronically to Contract Specialist Ashley N. Atkins by 11:00 AM ET on December 10, 2025. Potential respondents are required to provide company details, DUNS number, CAGE code, and socio-economic classifications in a detailed information table, and must refrain from discussing the requirement with program office members outside of the designated point of contact.
The procurement falls under NAICS code 541715 (Research and Development in the Physical, Engineering, and Life Sciences) with no set-aside designations applied. The project is structured as a three-phase effort over four years, encompassing pre-study preparation with Institutional Review Board activities, clinical study execution across multiple sites, and subsequent data analysis and scientific publication. No specific budget range or award value is disclosed in this pre-solicitation notice, nor are any incumbent contractors or potential competitors identified. The RFI emphasizes the market research nature of this inquiry and serves as an advance notice to potential contractors regarding the government's upcoming formal solicitation for these specialized clinical research services in the medical sciences sector.
Notice text
Please see the attached PDF document.
Files
Notice history
| Notice | Type | Posted |
|---|---|---|
| Malaria Radical Cure Drug Efficacy Clinical Study | Special Notice | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Reqeust for Information (RFI) Consumables and Reagents BPA - WRAIR Africa | — | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity